Scientific Expertise

Biogen is working to solve some of medicine’s greatest challenges among the most complex, devastating neurological and neurodegenerative diseases. The field of neuroscience is vast with many intersecting disciplines, therefore our strategy is to focus on four core and four emerging growth areas.


Core Growth Areas

We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise, and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society. As such, we continue to welcome collaborations with academic and industry partners around the world in the pursuit of transformative neuroprotective therapies.


Multiple Sclerosis & Neuroimmunology

Our deep commitment to understanding and treating multiple sclerosis (MS) is evidenced by a track record of successes and innovation in the treatment of that disease. Biogen has a unique portfolio of approved drugs to treat MS, ranging from different disease modifying treatments differentiated by route of administration, mechanism of action, and relative efficacy to address the inflammatory components of the disease, to symptomatic treatments. The need for continuing to seek new ways of treating MS is as important as ever.

We are undertaking a variety of approaches to further our understanding of the disease and how to treat it. These include applying human genetics to understand the basis of disease progression, investigating new approaches to repair damaged nerves in the central nervous system with the goal of improving pre-existing disability, and looking at ways of treating progressive forms of MS. We also have an active research program in neuroinflammation, studying its pathology across multiple neurological diseases.

Alzheimer's Disease & Dementia

Our heritage in neurology is built on years of research into the most complex neurodegenerative diseases and we bring this expertise and experience to our Alzheimer’s disease and dementia therapeutic area. Our strategically diverse portfolio of investigational products includes several assets targeting early-stage Alzheimer’s disease.

We are developing and incorporating advanced imaging and biomarker technologies into our programs to improve the ability to accurately diagnose this disease as early as possible.

Alzheimer’s disease and other dementias are complex and will likely require multiple therapeutic approaches. We continue to research underlying mechanisms and to identify new targets to address different pathways including post-translational modification of tau, synaptic plasticity, and neuroinflammation. Our efforts cross many scientific disciplines. We are capitalizing on the advances in molecular and cellular biology, and connecting them with human genetic discoveries. 

Along with building a team of expert scientists, clinicians, and technologists, we are also pursuing external collaborations to advance our Alzheimer’s disease programs. Collaboration is critical to our efforts and our external collaborations ensure our scientific teams and those from the world’s leading academic institutions are connected.



Our work in movement disorders builds on our neuroscience strengths. We currently have a preclinical and clinical portfolio around Parkinson’s disease (PD) and progressive supranuclear palsy (PSP) targeting core disease genetics and pathology. 

In Parkinson’s disease, our initial programs target α-synuclein, a validated PD target, through distinct approaches. Future programs aim to broaden the range of targets and modalities for PD, build a strong suite of disease-related biomarkers, and continue our productive interactions with patient associations and foundations who lead the way in PD research. 

PSP is a rare neurodegenerative disease, associated with insoluble tau aggregation throughout the brain and characterized by atypical Parkinsonism. In PSP, our program’s focus is to remove extracellular tau which may reduce the spreading of the abnormal form of this molecule, potentially slowing the progression of the disease.


Our efforts in neuromuscular disorders are focused on two main areas: spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).

We have brought forward the first and only approved therapy for SMA, and our scientists continue to work toward new therapeutics for SMA patients, including a gene therapy approach in collaboration with the University of Pennsylvania.

Despite the existence of two FDA-approved drugs, there are still no potent disease-modifying therapies for ALS. Our most advanced programs focus on the familial, inherited forms of ALS that collectively represent ~10% of all patients, and use antisense oligonucleotides to reduce the levels of the disease-triggering genes. We believe that smaller, quicker clinical trials will be particularly important as we take on the most frequent, sporadic cases of the disease. To take on this challenge, we have built a preclinical pipeline for evaluation of a wide range of therapeutic targets and modalities.


Emerging Growth Areas

Biogen has some of the world’s best neurologists and neuroscientists. We engage with physicians and scientific leaders around the world with the aim to further medical research. Biogen’s emerging growth areas derive from our deep expertise in the core growth areas. 



Acute brain injury, including stroke, traumatic brain injury, and seizures are leading causes of permanent disability in our society, and most patients who sustain them do not currently receive disease modifying therapies. In addition to our core expertise in areas such as neuroinflammation, blood-brain barrier integrity and neurorepair, we have an innovative portfolio of compounds that target peripheral immune cell infiltration, brain edema, glial cell activation, and cell death pathways, which have the potential to transform clinical care paradigms in acute brain injury. 



Neurocognitive Disorders

Almost 1 in 5, or 43.4 million, adults in the US experience psychiatric illness in a given year, with even higher rates seen in neurological, neurodegenerative and general medical settings. These symptoms result in diminished qualify of life, productivity and life expectancy, and as a result place substantial burden on patients, families, and the broader healthcare system. 

Building on recent advances in genetics, cognitive neuroscience, neuroimaging and pharmacology, as well as our access to a range of therapeutic modalities, Biogen aims to leverage its expertise in neurological diseases to deliver novel therapeutics. 


Chronic pain afflicts 10-20% of the world’s population (Treede et al, 2015), and is a leading cause of long-term disability. It exacts substantial psychological and financial costs on sufferers and society at large. 

Our approach to pain therapeutics is guided by several principles to improve probability of success, including selecting drug targets and pathways in rare genetic conditions, testing new drug candidates in patient populations with severe pain conditions, and exploring the possibility of combining multiple approaches for engaging a drug target. Our development of inhibitors to Nav1.7, a sodium channel expressed in pain circuits, exemplifies this approach, and is currently in clinical trials. 


The retina is an extension of the CNS developmentally, anatomically and functionally and our extensive expertise in disorders of the CNS has been instrumental in shaping Biogen’s ophthalmology portfolio.

In collaboration with our partner AGTC, we are engaged in early clinical gene therapy programs for two rare inherited retinal disorders - X-linked retinoschisis (XLRS) and X-linked retinitis pigmentosa (XLRP). We also continue to explore several modalities beyond gene therapy for engaging drug targets, and have expanded our discovery efforts with other innovative industry and academic partnerships in the pursuit of delivering transformative therapies to patients with vision loss caused by disorders of the retina and the optic nerve. 


Through the use of our core platforms and modalities, Biogen is bringing new scientific understanding to diseases for which there are no adequate treatments. These research platforms are built to support key drug modalities used at Biogen including small molecules, biologics, antisense oligonucleotides and gene therapy.  



Our core research platforms are designed to predict drug concentrations in blood and tissues using physiologic based pharmacokinetic modeling approaches, and linking these concentrations to drug effects using biomarker, imaging, safety and clinical endpoints.



Biomarkers are indicators of normal or pathogenic biological processes, or pharmacologic response to a drug or other therapeutic intervention. We are industry pioneers in the use of biomarkers for assessing drug safety and efficacy in MS and SMA, and are breaking new ground in clinical trials of neurodegenerative diseases through our innovative use of positron emission tomography (PET) and magnetic resonance imaging (MRI) to select patients, monitor safety, and assess the biological effects of treatment.

We work within our laboratories and with external collaborators to discover and validate novel assays, imaging probes, data analysis methods, and technologies across Biogen’s disease areas of interest. Our expertise in biomarker science combined with a deep knowledge of drug discovery and development ensures appropriate context of use.


Drug Metabolism & Pharmacokinetics (DMPK) enables the discovery and development of safe and effective medicines by providing insight into the mechanisms of drug absorption, distribution, metabolism, and excretion (ADME). 

We utilize industry-leading experimental and mathematical models to assess the biochemical fate of lead molecules and clinical candidates and understand how they break down and are absorbed, distributed, metabolized, and excreted by the body. Specific to neuroscience, we enhance our analyses using specialized CNS-targeted delivery and continuous cerebrospinal fluid (CSF) sampling techniques to assess distribution kinetics, giving us critical pharmacodynamic information to help determine optimal dosing and scheduling.  


After defining the behavior of a drug candidate in various preclinical models, we then apply that information in the human context, using clinical pharmacology and pharmacometrics to characterize the drug disposition in the body over time (i.e., pharmacokinetics), and to link drug levels in blood/tissues with drug effects on biomarkers, efficacy, and safety (i.e., pharmacodynamics). 

Given our focus in neuroscience, our core research platforms are designed to predict drug concentrations in blood, plasma, and tissues in the CNS using physiologic based pharmacokinetic modeling approaches, with translational and drug-disease models to better characterize and predict drug effects throughout the nervous system, (i.e., PET imaging, CSF measurements) and link these early biomarkers to patient outcome. 


We use extensive screening tests to select and advance safe targets and molecules from discovery into development. Our expert team of toxicologists, pathologists, and study managers begin their project involvement at an early stage of drug discovery and carry these responsibilities through all phases of clinical development and marketed products.  


Biogen discovers and develops therapeutics in multiple drug modalities, including small molecules, biologics, antisense oligonucleotides, and gene therapy. 



Small molecule therapeutics can often be taken as an oral pill, distributing into cells and tissues, including the brain, differently than other therapeutic modalities.  

Through a series of rational design cycles, our work in small molecules aims to incrementally improve a drug candidate’s physicochemical properties, to enable it to work as a medicine. This process begins with screening vast libraries of molecules to find starting points and model how these compounds might interact with their targets. We utilize medicinal chemistry and synthesis, testing molecules in functional assays that replicate the target and tell us whether the small molecules are binding in the way we expected or if they are having off-target effects.  

The process of rational design results in small molecule candidates that have appropriate characteristics to be effective in pharmacodynamic models that mimic human disease, and are safe for patients.


Therapeutic proteins, also referred to as biologics, differ dramatically from traditional small molecule drugs. Biologics, which include monoclonal antibodies, growth factors, cytokines, enzymes and many other types of proteins, are often as much as a thousand times the size of small molecule drugs, and are manufactured in living cells rather than through chemical synthesis. Although this type of drug is much more complicated to make and characterize, using biologics allows scientists to attack serious disease in ways that might not be possible with other technologies. Antibodies (and antibody-like proteins) have become the most common type of biologic because of the exquisite specificity and long duration of action of this type of molecule.

As one of the oldest independent biotechnology companies in the world, Biogen scientists have contributed to the development of many of these medicines, including recombinant interferons, antibodies and several experimental neurology treatments in our clinical development portfolio such as opicinumab.


The approval of the first and only treatment for spinal muscular atrophy by an antisense oligonucleotide (ASO) spearheaded Biogen’s commitment to development of ASOs as a newly emerging therapeutic modality to treat severe neurological diseases, working with our collaboration partner Ionis Pharmaceuticals.

ASOs are synthetic single stranded nucleic acids consisting of 8-50 nucleotides which bind to RNA to interfere with target gene expression. ASOs utilize several distinct mechanisms to alter RNA and either restore desired protein expression or reduce and modify a toxic protein, enabling them to be used as a powerful modality to establish convincing proof of biological function. 


Gene therapy represents the newest addition to Biogen’s suite of therapeutic modalities. By introducing nucleic acids into a patient’s cells, this method provides the potential to repair, inhibit or replace the defective genes that lead to disease. Gene therapy expands our potential to treat previously intractable diseases by capitalizing on recent advances in our understanding of human genetics.